Publications - Released in 2020
This technical guidance describes the methods and implementation considerations to monitor the prevalence of HIV drug resistance among PrEP users diagnosed with HIV through a cross-sectional survey. The outcomes of the survey will be used to inform the selection of maximally effective first-line combination antiretroviral therapy for PrEP users who acquire HIV.
Downloads
Publication(1.36 MB)
Organizations
- World Health Organization (WHO)